Equities

Ascentage Pharma Group International

Ascentage Pharma Group International

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)42.10
  • Today's Change1.05 / 2.56%
  • Shares traded928.50k
  • 1 Year change+62.86%
  • Beta1.2514
Data delayed at least 15 minutes, as of Nov 14 2024 03:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,0691,4761,707
Total Receivables, Net1646176
Total Inventory169.453.93
Prepaid expenses646157
Other current assets, total312941
Total current assets1,3441,6361,885
Property, plant & equipment, net957649844
Goodwill, net252525
Intangibles, net858460
Long term investments1937428
Note receivable - long term------
Other long term assets107.8046
Total assets2,5002,8302,940
LIABILITIES
Accounts payable729671
Accrued expenses12612175
Notes payable/short-term debt1201400
Current portion long-term debt/capital leases49637849
Other current liabilities, total120147165
Total current liabilities934881361
Total long term debt1,1791,2741,035
Total debt1,7961,7931,084
Deferred income tax111214
Minority interest10----
Other liabilities, total306254296
Total liabilities2,4402,4221,705
SHAREHOLDERS EQUITY
Common stock0.200.180.18
Additional paid-in capital5,9515,3935,342
Retained earnings (accumulated deficit)(5737)(4799)(3887)
Treasury stock - common(21)(27)0.00
Unrealized gain (loss)------
Other equity, total(133)(159)(221)
Total equity604091,235
Total liabilities & shareholders' equity2,5002,8302,940
Total common shares outstanding290265263
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.